Current Report Filing (8-k)
October 08 2019 - 11:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 8, 2019
MCTC HOLDINGS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
|
|
333-146404
|
|
83-1754057
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of incorporation)
|
|
|
|
Identification No.)
|
520 S Grand Avenue
Suite 320
Los Angeles, CA
|
|
90071
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (310) 986-4929
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
□
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
□
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
□
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
□
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
MCTC Holdings, Inc. (the “Company”)
a Delaware corporation (the “Company”) makes the following disclosures pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934, generally referred to as Regulation FD Disclosure. Over the coming days, the Company plans to discuss the
below items with selected shareholders and potential investors and is thus making these disclosures in advance of these discussions
in order to ensure all Company stakeholders are privy to this information.
On October 8, 2019, the Company completed an
important milestones in its research and development program via creation of solid polymeric nanoparticles of cannabinoids with
the sustained release properties targeted by the Company. The initial set of particles produced in the laboratory were confirmed
to be in the nano-scale via scanning electron microscopy. The Company plans to begin testing on the confirmed samples. The Company
achieved the additional goal of the production of polymeric scaffolds of vitamin C and hyaluronic acid able to maintain integrity
in the presence of water. Such scaffolds are targeted at transdermal and cosmetic applications. Both the sustained release particles
and the polymeric scaffolds have been development objectives for the Company.
This current report on Form 8-K may contain
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company
intends forward-looking terminology such as "believes," "expects," "may," "will," "should,"
"anticipates," "plans," or similar expressions to identify forward-looking statements. Such statements are
subject to certain risks and uncertainties, which could cause the Company's actual results to differ materially from those anticipated
by the forward-looking statements. These risks and uncertainties include, but are not limited to, risks described more fully the
Company's Annual Report on Form 10-K and it the Company’s recently filed Registration Statement on Form S-1, which is expressly
incorporated herein by reference, and other factors as may periodically be described in the Company's filings with the SEC.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
MCTC HOLDINGS, INC.
|
|
|
|
|
|
Date: October 8, 2019
|
|
/s/ Arman Tabatabaei
|
|
|
|
Name: Arman Tabatabaei
|
|
|
|
Title: Chief Executive Officer
|
|